Regeneron Pharmaceuticals ( (REGN) ) has released its Q4 earnings. Here is a breakdown of the information Regeneron Pharmaceuticals presented to its investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the invention, development, and commercialization of medicines for serious diseases, leveraging unique proprietary technologies to drive its advancements in the industry.
In its latest financial report, Regeneron Pharmaceuticals detailed strong revenue growth for the fourth quarter and full year 2024, and announced initiatives such as the initiation of a quarterly dividend and an increased share repurchase program. The company’s strategic focus remains on its key products and expanding its R&D pipeline.
Key financial highlights include a 10% increase in fourth-quarter revenues to $3.79 billion and an 8% increase in full-year revenues to $14.20 billion. Dupixent saw a significant 22% increase in global net sales for the year. Meanwhile, Libtayo’s global sales rose by 40%. The company declared a cash dividend of $0.88 per share and authorized an additional $3 billion share repurchase program, enhancing shareholder returns.
Regeneron also reported progress in its clinical pipeline, with positive Phase 3 results for EYLEA HD and Libtayo, along with several regulatory submissions to the FDA. The company continues to expand its investigational candidates, reflecting its commitment to advancing treatment options across various disease states.
Looking forward, Regeneron aims to build on its solid financial and operational momentum by continuing to focus on its blockbuster medicines and progressing its extensive pipeline of investigational candidates, with expansive market potential expected in 2025.
